1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials
MESQUITA Y, CALVI I, MARQUES I, CRUZ S, PADRAO E, CARDOSO R, MOURA F, RAFALSKIY V. 1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials. Diabetes 2023, 72 DOI: 10.2337/db23-1704-p.Peer-Reviewed Original ResearchMean differenceDual glucose-dependent insulinotropic polypeptideOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsSafety of tirzepatideGlucose-dependent insulinotropic polypeptideCo-primary endpointsGastrointestinal side effectsWeight lossType 2 diabetesRandomized controlled trialsReceptor agonistsBody weight changesTherapeutic optionsAdverse eventsTirzepatidePooled analysisSide effectsPlaceboWeight managementControlled trialsMeta-analysisBody weight